Get started
Author

Marcelyne Joseney-Antoine

Interim Results from a Phase 1/2 Clinical Study of Lentiglobin Gene Therapy for Severe Sickle Cell Disease
2016 · Julie Kanter, Mark C. Walters, et al. · Blood · 75
A Phase 1/2 Trial of Investigational Spk-8011 in Hemophilia a Demonstrates Durable Expression and Prevention of Bleeds
2018 · Katherine A. High, Lindsey A. George, et al. · Blood · 56
Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease
2026 · Ashish O. Gupta, Akshay Sharma, et al. · New England Journal of Medicine · 38
Successful Plerixafor-Mediated Mobilization, Apheresis, and Lentiviral Vector Transduction of Hematopoietic Stem Cells in Patients with Severe Sickle Cell Disease
2017 · John F Tisdale, Francis J. Pierciey, et al. · Blood · 21
Initial Results from the BEACON Clinical Study: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises
2024 · Ashish O. Gupta, Akshay Sharma, et al. · Blood · 17
Update from the Hgb-205 Phase 1/2 Clinical Study of Lentiglobin Gene Therapy: Sustained Clinical Benefit in Severe Hemoglobinopathies
2016 · Jean-Antoine Ribeil, Salima Hacein-Bey-Abina, et al. · Blood · 8
Robust HbF induction and improvement of anemia and hemolysis with base editing in sickle cell disease: Safety and efficacy findings from the ongoing BEACON study
2025 · Ashish Gupta, Akshay Sharma, et al. · Blood · 2
PDF
Safety and Efficacy of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) for the Treatment of Sickle Cell Disease with Severe Vaso-Occlusive Crises: Results from the Ongoing Phase 1/2 Beacon Study
2025 · Ashish O. Gupta, Akshay Sharma, et al. · Transplantation and Cellular Therapy
Works count: 8
Citation count: 217
H-index: 6
I10-index: 5
Year
Topic
Type